‘Masked’ cancer drug sneaks through body to deliver anti-tumor treatment with fewer side effects
Study finds patients with mitral annulus calcification at higher risk of heart valve and cardiovascular disease
1 June 2022Psoriasis tied to higher risk for nonalcoholic fatty liver disease
1 June 2022‘Masked’ cancer drug sneaks through body to deliver anti-tumor treatment with fewer side effects
Many cancer treatments are notoriously savage on the body; they attack healthy cells at the same time as tumor cells, causing a plethora of side effects. Now, researchers at the University of Chicago’s Pritzker School of Molecular Engineering (PME) have designed a method to keep one promising cancer drug from wreaking such havoc. The team has engineered a new “masked” version of the immunotherapy drug interleukin-12 that is activated only when it reaches a tumor. The research on the molecule, also known as IL-12, is described in the journal Nature Biomedical Engineering.
